Advertisement

Topics

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celladon Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of August 31, 2015 -- CLDN

20:00 EDT 19 Jul 2015 | Globe Newswire

NEW YORK, July 20, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Celladon Corporation ("Celladon") (NASDAQ:CLDN) between July 7, 2014 and June 25, 2015.  

You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of California. If you purchased or otherwise acquired Celladon Corporation securities between July 7, 2014 and June 25, 2015, your rights may be affected by this action. To get more information go to:

http://zlk.9nl.com/celladon-cldn

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or failed to disclose adverse information regarding the Company's prospects for its lead drug candidate, MYDICAR, for treating enzyme deficiency in heart failure patients that results in inadequate pumping of the heart.

On April 26, 2015, Celladon announced that the Company's Phase 2b CUPID2 trial of MYDICAR did not meet its primary and secondary goals. Then on June 1, 2015, Celladon issued a press release announcing the abrupt resignation of the Company's Chief Executive Officer. Then, on June 26, 2015, Celladon announced the suspension of its plans for further research or development of its MYDICAR program and other pre-clinical programs, indicating there was a possibility that the Company could be liquidated with net cash available to shareholders of $25-$30 million.

If you suffered a loss in Celladon you have until August 31, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Levi & Korsinsky, LLP
         30 Broad Street - 24th Floor
         New York, NY 10004
         Tel: (212) 363-7500
         Toll Free: (877) 363-5972
         Fax: (212) 363-7171
         www.zlk.com
NEXT ARTICLE

More From BioPortfolio on "SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celladon Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of August 31, 2015 -- CLDN"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...